Slide 1: 4basebio: Innovation in Gene Synthesis and Delivery
4basebio Innovation in Gene Synthesis and Delivery June 2024 1
Slide 2: Disclaimer
Disclaimer This document is intended for shareholders, prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estim
Slide 3: 4basebio Management Team
4basebio Management Team Dr. Heikki Lanckriet, PhD. David Roth CEO / CSO CFO • Chartered accountant with a background in professional services, private equity and listed • 20+ years commercial and scientific experience in life companies, where he has held senior positions over the past 20 years scie
Slide 4: Agenda
Agenda I. Company Overview II. Market Opportunity & 4bb’s Competitive Positioning III. Competitive Differentiators IV. Commercial & Revenue Visibility V. Financial Overview VI. Summary & Outlook 4
Slide 5: I. Company Overview
Company Overview iidbase bio 5
Slide 6: Innovative Technology Platforms for CGT & Vaccine Applications
Innovative Technology Platforms for CGT & Vaccine Applications 4basebio overview Cambridge, UK Proprietary Enzyme Manufacturing • 4basebio is an innovative and disruptive developer, manufacturer and supplier of proprietary synthetic DNA for gene therapies and DNA vaccines, and provides solutions for
Slide 7: Technology Platforms
Commercialising Innovative & Disruptive Technology Platform for Genetic Medicine & Vaccines 4bb Synthetic DNA HermesTM nanoparticles Synergistic • Enzymatically manufactured Key Benefits vs. Plasmid DNA Potential • Proprietary, targeted non-viral vectors for delivery Synthetic DNA template technolog
Slide 8: Key Milestones Achieved – 2023
Key Milestones Achieved – 2023 Doubled revenue Delivered over 25 fee paying Expanded customer headcount projects 2023 First sale of 6 novel patent HQ of filings synthetic DNA First order for GMP grade synthetic DNA 8
Slide 9: Strong Leadership Team with a Structured Organisation Addressing Key Functions
Strong Leadership Team with a Structured Organisation Addressing Key Functions Senior Management 3 David Roth Heikki Lanckriet Amy Walker CFO CEO VP Research & BD 16 14 25 30 14 GFA Platform QA / Application Validation Client Projects (incl. Lab Management, Development Manufacturing HR, IT, Faciliti
Slide 10: II. Market Opportunity & 4basebio's Competitive Positioning
Market Opportunity & 4basebio’s II. Competitive Positioning 10
Slide 11: Synthetic DNA Market Opportunity to Replace Plasmid DNA
Synthetic DNA has the Market Opportunity to Replace Plasmid DNA as the Critical Starting Material in Blockbuster Cell & Gene Therapy and Vaccines Development Plasmid DNA Market C> and mRNA Vaccines: a High-Growth, Increasingly Relevant Market Segment mRNA Gene Editing AAV Lentiviral DNA Vaccines p
Slide 12: Technology Platform with Proprietary Synthetic DNA Products
Technology Platform with Proprietary and Game-Changing Synthetic DNA Products Serving Attractive Application-Specific Market Opportunities Application End-Market Opportunity(1) 4bbDNA Products DNA Structure Description ~$30bn • Partially opened, linear, double stranded DNA IVT mRNA opDNATM product •
Slide 13: Ideally Positioned to Deliver Cost-Effective-to-Scale DNA vs. Incumbents
Ideally Positioned to Deliver Cost-Effective-to-Scale DNA vs. Incumbent Plasmid DNA, De-Novo and Alternative Amplification Based Approaches DNA competitive landscape Leader in Synthetic DNA Incumbent DNA Other Plasmid PCR RCA-based source for C> RCA platforms are key and vaccines Amplification bas
Slide 14: III. Competitive Differentiators
III. Competitive Differentiators 14
Slide 15: 4bb Synthetic DNA is Superior to Plasmid DNA Across Several Factors
4bb Synthetic DNA is Superior to Plasmid DNA Across Several Factors, Offering a Superior Solution to Big Pharma, Biotechs and Institutions ✓ Cost-Effectiveness ✓ Flexibility of Scale ✓ Utility of Application / Complexity 10g opDNATM oeDNATM 50mg hpDNATM plasmid 4bb DNA Production at any scale osDNAT
Slide 16: Next Generation LNP Delivery System (Hermes) for Nucleic Acid and Protein Payloads
Next Generation LNP Delivery System (HermesTM) for Nucleic Acid and Protein Payloads, Enabling Enhanced Stability And Tailored To Client Applications HermesTM Overview Key Benefits • Targeted, non-viral delivery, as provided by our Hermes technology, will enable the Safety: development of safer, mor
Slide 17: IV. Commercial and Revenue Visibility
IV. Commercial and Revenue Visibility 17
Slide 18: Go-to-Market Strategy: Ideal Partner from Development to Commercialisation
Go-to-Market Strategy: 4basebio is the Ideal Partner from Development, through the Clinic and in Commercialisation Historically, Customers Enter in Development Stage Client might evaluate product DNA Commercial Relationship Start ‘Off-The-Shelf’ Construct performance vs. pDNA using in-house Typicall
Slide 19: Current Client Base
Current Client Base By application By region By client type 7% 2% 4% 13% 24% 21% 10% mRNA 12% Split 36% 6% 52% 21% 64% Therapy 4% Vaccines 59% 25% 40% AAV DNA vaccine Gene editing (1) Large Pharma / Biotech Biotech: >$500m (1) Biotech: <$500m CDMO mRNA Other US UK EU APAC Strategics Academic Growing
Slide 20: A Recent mRNA Customer Journey Case Study - Biotech
A Recent mRNA Customer Journey Case Study - Biotech 2022 2023 2024 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Research Use Only (RUO) Customer Profile October January Initial customer Shipment 1: • US-based Biotech working on interaction opDNA + mRNA mRNA vaccines for different applications, including November March infe
Slide 21: A Recent mRNA Customer Journey Case Study - Pharma
A Recent mRNA Customer Journey Case Study - Pharma 2023 2024 Sept Oct Nov Dec Jan Feb March April May June July Aug Sept Q4 Research Use Only (RUO) Customer Profile • Global pharma company interested in using synthetic DNA for seasonal vaccines and pandemic responses - inbound request Initial • Drug
Slide 22: Significant Momentum in Client Engagement with New Contract Wins
Significant Momentum in Client Engagement with New Contract Wins and Progression into the Clinic Evolution of Near-Term Project Share Evolution of Near-Term Revenue Share # of Fee-Paying Projects Significant proportion of near- Early Clinical GMP term value derives from clinical progression of £12-1
Slide 23: V. Financial Overview
V. Financial Overview it4basebio 23
Slide 24: Financial Overview
Financial Overview Income Statement Cashflows [in £‘ 000] 2023 2022 Com m e nts [in £ ’ 000 ] 2023 2022 Com m e nts Revenues 506 268 • Doubling of Net loss for the period (7,665) (5,150) • Operating cashflows revenue reflect increasing Cost of goods sold (166) (29) Income taxes (689) (779) activity
Slide 25: Financial Overview
Financial Overview Balance Sheet - Assets Balance Sheet – Equity and Liabilities [in £ ’ 000 ] 2023 2022 Com m e nts [in £ ’ 000 ] 2023 2022 Com m e nts Assets • Further property Liabilities • Operating cashflows additions reflect increasing Intangible assets 2,669 2,124 Financial liabilities (392)
Slide 26: Financial Overview: 2024 Position
Financial Overview 2024 Position • Strong revenue growth across the course of the year; precise timing uncertain • Operating Expenditure to increase with scaling of business • Headcount to mature around 110 staff • Continued funding of activities through 2Invest AG loan facility 26
Slide 27: VI. Summary and Outlook
VI. Summary and Outlook it4basebio 27
Slide 28: Inflection Points Towards Adoption
Inflection Points Towards Adoption Exponential Adoption Phase • Displacement of incumbent plasmid DNA • Clinical trials in multiple therapeutic application areas Commercialisation GMP ready Licensed drug products on market • Supply of HQ batches for GLP tox studies • Entry to clinic as critical star
Slide 29: 2024 – Key Objectives
2024 – Key Objectives 2024 Deliverables • Build on commercial momentum and drive revenues • Good GMP visibility • Timing and cadence of orders remains client dependent • Uneven revenue recognition • Advance GMP certification • Objective to obtain MHRA IMP licence for Drug Substance manufacture in th
Slide 30: Commercialising Innovative & Disruptive Technology Platforms for Genetic Medicine & Vaccines
Commercialising Innovative & Disruptive Technology Platforms for Genetic Medicine & Vaccines Proprietary and disruptive technology in DNA synthesis offering a differentiated cost-effective-to-scale, quicker, safer and more flexible solution vs. incumbent methods of DNA manufacturing, with unparallel